EF Hutton analyst Tim Moore maintains CEL-SCI (AMEX:CVM) with a Buy and lowers the price target from $17 to $16.
Stephens & Co. Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $52
Stephens & Co. initiates coverage on Veracyte (NASDAQ:VCYT) with a Overweight rating and announces Price Target of $52.